Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow IPHA by emailGet an email when IPHA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IPHA, unsubscribe in one click. Privacy
📣 What IPHA Says Is Next
H2 2026 · “Enrollment in the trial is complete, and data readout is expected in H2 2026.”
Company press release, Sep 17, 2026 · SEC filing
Q1 2027 · “This triggers a USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027.”
Company press release, Sep 17, 2026 · SEC filing
Q1 2027 · ““With the TELLOMAK-3 Phase 3 study initiated, we are targeting the first patient in the study in Q1 2027 as we work toward a filing for accelerated approval in Sézary syndrome.”
Company press release, Sep 17, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full IPHA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IPHA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.